Compare Stocks: XRTX, CTXR, SCNX, and ADIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.60 -1.6%	$3.64	$1.31 ▼ $10.75	$14.70M	1.39	84,238 shs	63,520 shs
CTXR Citius Pharmaceuticals	$0.60 -4.3%	$0.59	$0.47 ▼ $2.19	$16.53M	1.03	1.01 million shs	360,730 shs
SCNX Scienture	$0.39 +3.7%	$0.39	$0.24 ▼ $2.60	$16.18M	3.26	3.51 million shs	273,313 shs
XRTX XORTX Therapeutics	$2.34 -4.1%	$2.10	$1.73 ▼ $7.05	$4.25M	0.73	10,716 shs	24,230 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-9.97%	+70.21%	+133.33%	-41.44%
CTXR Citius Pharmaceuticals	0.00%	+0.32%	-4.73%	-8.06%	-56.05%
SCNX Scienture	0.00%	-12.39%	+3.20%	-4.60%	-61.75%
XRTX XORTX Therapeutics	0.00%	+14.71%	+15.84%	+1.74%	-42.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.60 -1.6%	$3.64	$1.31 ▼ $10.75	$14.70M	1.39	84,238 shs	63,520 shs
CTXR Citius Pharmaceuticals	$0.60 -4.3%	$0.59	$0.47 ▼ $2.19	$16.53M	1.03	1.01 million shs	360,730 shs
SCNX Scienture	$0.39 +3.7%	$0.39	$0.24 ▼ $2.60	$16.18M	3.26	3.51 million shs	273,313 shs
XRTX XORTX Therapeutics	$2.34 -4.1%	$2.10	$1.73 ▼ $7.05	$4.25M	0.73	10,716 shs	24,230 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-9.97%	+70.21%	+133.33%	-41.44%
CTXR Citius Pharmaceuticals	0.00%	+0.32%	-4.73%	-8.06%	-56.05%
SCNX Scienture	0.00%	-12.39%	+3.20%	-4.60%	-61.75%
XRTX XORTX Therapeutics	0.00%	+14.71%	+15.84%	+1.74%	-42.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.40	Hold	$15.63	179.02% Upside
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	730.43% Upside
SCNX Scienture	2.00	Hold	$1.50	280.71% Upside
XRTX XORTX Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XRTX, CTXR, SCNX, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/17/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	XRTX XORTX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	ADIL Adial Pharmaceuticals	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00
6/15/2026	ADIL Adial Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy
6/11/2026	ADIL Adial Pharmaceuticals	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$4.75 per share	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
SCNX Scienture	$430K	37.62	N/A	N/A	$1.73 per share	0.23
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	$1.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	11/18/2026 (Estimated)
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/12/2026 (Estimated)
XRTX XORTX Therapeutics	-$2.66M	-$2.73	N/A	N/A	N/A	N/A	-137.85%	-108.16%	11/12/2026 (Estimated)

Latest XRTX, CTXR, SCNX, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2026	Q2 2026	XRTX XORTX Therapeutics	N/A	-$1.05	N/A	-$1.05	N/A	N/A
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
SCNX Scienture	0.15	3.04	2.97
XRTX XORTX Therapeutics	N/A	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
CTXR Citius Pharmaceuticals	16.88%
SCNX Scienture	5.68%
XRTX XORTX Therapeutics	0.23%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	8.00%
CTXR Citius Pharmaceuticals	4.99%
SCNX Scienture	21.39%
XRTX XORTX Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	2.63 million	2.42 million	No Data
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
SCNX Scienture	N/A	41.06 million	32.28 million	N/A
XRTX XORTX Therapeutics	N/A	1.82 million	1.69 million	Not Optionable

XRTX, CTXR, SCNX, and ADIL Headlines

Recent News About These Companies

XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed

August 28 at 12:11 PM | rttnews.com

XORTX Announces Termination and Postponement of Investor Relations Program

August 28 at 7:00 AM | globenewswire.com

XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet

August 17, 2026 | tipranks.com

XORTX Therapeutics Inc.

August 11, 2026 | barrons.com

XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo

August 4, 2026 | tipranks.com

XORTX Therapeutics Inc. annonce la démission d'Anthony Giovinazzo de son poste d'administrateur

August 2, 2026 | zonebourse.comZ

XORTX Therapeutics Inc.: XORTX Announces Director Resignation

August 1, 2026 | finanznachrichten.de

XORTX Announces Director Resignation

July 31, 2026 | financialpost.comF

XORTX Announces Director Resignation

July 31, 2026 | globenewswire.com

XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight

July 29, 2026 | tipranks.com

XORTX Appoints New Director

July 29, 2026 | financialpost.comF

XORTX Appoints New Director

July 29, 2026 | globenewswire.com

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

June 15, 2026 | financialpost.comF

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

June 15, 2026 | globenewswire.com

XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing

June 12, 2026 | tipranks.com

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

June 12, 2026 | financialpost.comF

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

June 12, 2026 | globenewswire.com

XORTX Announces Closing of US$5 Million Public Offering

May 19, 2026 | financialpost.comF

XORTX Announces Closing of US$5 Million Public Offering

May 19, 2026 | globenewswire.com

XORTX files Q1 2026 unaudited results showing lower cash and equity

May 19, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX, CTXR, SCNX, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$5.60 -0.09 (-1.58%)

As of 08/28/2026 04:00 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Citius Pharmaceuticals NASDAQ:CTXR

$0.60 -0.03 (-4.28%)

As of 08/28/2026 04:00 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Scienture NASDAQ:SCNX

$0.39 +0.01 (+3.68%)

As of 08/28/2026 04:00 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

XORTX Therapeutics NASDAQ:XRTX

$2.34 -0.10 (-4.10%)

As of 08/28/2026 03:59 PM Eastern

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XRTX, CTXR, SCNX, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XRTX, CTXR, SCNX, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XRTX, CTXR, SCNX, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX, CTXR, SCNX, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Citius Pharmaceuticals NASDAQ:CTXR

Scienture NASDAQ:SCNX

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XRTX, CTXR, SCNX, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XRTX, CTXR, SCNX, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XRTX, CTXR, SCNX, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX, CTXR, SCNX, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Citius Pharmaceuticals NASDAQ:CTXR

Scienture NASDAQ:SCNX

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools